Further studies demonstrated that FSP1 expression level conferred ferroptosis resistance of KEAP1-mutant or -deficient lung cancer cells, since FSP1 inhibition by genetic knockout or pharmacological inhibitor re-sensitized KEAP1-deficient cells to ferroptosis, while FSP1 overexpression promoted ferroptosis resistance [13]. This evidence concerns the gene AIFM2 and lung carcinoma.